Company Overview
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Dec 2025 Revenue of $2.19M (-39.5% YoY); net profit $-24.19M.
- Trailing 12 Months Year-on-year growth — revenue +2778.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 2,778.50% |
Stock Price Performance
| 1 Year: | -24.71% |
| 6 Months: | -18.01% |
| 3 Months: | +16.13% |
| 1 Month: | +3.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALGS Aligos Therapeutics, Inc. PHARMA | 5.76 | -0.75 | $31.36M | 0.00% | -130.74% | -113.59% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 140.00K | 4.29M | 1.08M | 694.00K | 1.06M | 1.25M | 311.00K | 965.00K | 741.00K | 2.83M | 0 |
| Operating Income | -14.50M | -20.72M | -21.27M | -21.56M | -27.74M | -29.57M | -33.07M | -35.56M | -20.39M | -18.95M | -23.92M | -19.14M | -19.07M | -22.05M | -26.41M | -20.13M | -19.24M | -18.57M | -28.36M | -26.93M | -1.89M |
| Net Income | -14.05M | -20.03M | -20.80M | -33.30M | -27.67M | -29.82M | -33.12M | -35.62M | -19.92M | -18.62M | -22.95M | -18.79M | -18.04M | -34.86M | 5.06M | -19.26M | 43.09M | -15.86M | -31.54M | -23.04M | -1.50M |
| Diluted EPS | - | - | - | - | - | - | -0.78 | -0.84 | -0.47 | -0.44 | -0.53 | -0.43 | -10.37 | -5.58 | 0.81 | -3.07 | -2.11 | -1.53 | -3.04 | -2.21 | -0.14 |
| R&D Expense | 11.73M | 17.30M | 17.18M | 17.33M | 22.87M | 24.55M | 28.13M | 31.68M | 16.51M | 17.79M | 18.14M | 16.78M | 15.87M | 16.37M | 21.10M | 16.77M | 14.50M | 13.98M | 23.94M | 23.35M | 24.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 6.19M | 3.61M | 2.19M |
| Operating Income | -54.04M | -97.83M | -128.32M | -97.58M | -88.13M | -89.15M | -87.98M |
| Net Income | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M | -24.19M |
| Diluted EPS | - | - | - | -2.25 | -34.20 | -20.94 | -2.45 |
| R&D Expense | 44.04M | 79.89M | 104.15M | 85.08M | 73.04M | 70.27M | 69.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 146.52M | 265.30M | 235.37M | 146.69M | 151.53M | 70.09M | 88.53M |
| Total Equity | -13.75M | -64.89M | 220.04M | 184.73M | 103.90M | 92.08M | -28.97M | 53.55M |
| Cash & Equivalents | - | 69.56M | 220.38M | 186.82M | 81.35M | 135.70M | 37.00M | 18.30M |
| Total Liabilities | - | 29.33M | 45.26M | 50.64M | 42.79M | 59.45M | 99.07M | 34.99M |
| Current Liabilities | - | 13.82M | 30.27M | 38.96M | 33.13M | 23.91M | 21.74M | 21.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.77M | -74.26M | -115.66M | -79.39M | -79.00M | -80.74M | -82.50M |
| Investing Cash Flow | 6.79M | 32.76M | 3.02M | -26.29M | 44.98M | -18.28M | -37.83M |
| Financing Cash Flow | 85.53M | 192.35M | 78.68M | 164.00K | 88.33M | 355.00K | 101.64M |
| Capital Expenditure | -2.79M | -2.06M | -892.00K | -943.00K | -19.00K | -130.00K | - |
| Free Cash Flow | -49.55M | -76.33M | -116.55M | -80.33M | -79.02M | -80.87M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -1,423.5% | -2,469.0% | -4,024.9% |
| Net Margin % | - | - | - | - | -1,416.2% | -3,633.6% | -1,106.7% |
| ROE % | 80.5% | -49.3% | -69.5% | -92.4% | -95.2% | 452.9% | -45.2% |
| ROCE % | -40.7% | -41.6% | -65.3% | -85.9% | -69.1% | -184.4% | -130.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 7.11% | 444.11K | $2.33M |
| 2 | Alyeska Investment Group, L.p. | 6.60% | 412.00K | $2.16M |
| 3 | Sio Capital Management, LLC | 5.24% | 327.24K | $1.71M |
| 4 | Marshall Wace LLP | 3.95% | 246.58K | $1.29M |
| 5 | Woodline Partners LP | 2.84% | 177.36K | $929.38K |
| 6 | Vanguard Capital Management LLC | 2.81% | 175.54K | $919.85K |
| 7 | Baker Bros. Advisors, LP | 1.33% | 83.06K | $435.21K |
| 8 | HHLR Advisors, LTD | 1.22% | 76.25K | $399.53K |
| 9 | Shaw D.E. & Co., Inc. | 1.06% | 66.46K | $348.27K |
| 10 | UBS Group AG | 0.96% | 59.99K | $314.33K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALGS
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Cali…
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and vi…
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseas…
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Topline data expected to be available late 3Q2027SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel thera…
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral dis…
ALGS — Frequently Asked Questions
What is the current share price of Aligos Therapeutics, Inc. (ALGS)?
As of 2026-09-19 21:16 PDT, Aligos Therapeutics, Inc. (ALGS) trades at $5.76 on NasdaqCM. Its 52-week range is $4.08 to $13.30.
What is the market capitalisation of ALGS?
Aligos Therapeutics, Inc. (ALGS) has a market capitalisation of $31.36M on NasdaqCM.
What is the P/E ratio of ALGS?
ALGS trades at a trailing price-to-earnings (P/E) ratio of -0.75. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of ALGS?
ALGS has a return on equity (ROE) of -113.59%. Its return on capital employed (ROCE) is -130.74%.
Is ALGS a good stock to buy?
This page provides a data-driven analysis of Aligos Therapeutics, Inc. (ALGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.